Gut check: Can cost-effectiveness analysis help eliminate gastric cancer in Asia?

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 5, 2007, Pages 873-874

  Ramsey, Scott D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE;

ATROPHIC GASTRITIS; BREATH ANALYSIS; CANCER DIAGNOSIS; CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NOTE; PRIORITY JOURNAL; STOMACH CANCER; STOMACH MUCOSA; TREATMENT OUTCOME;

CHEMOPREVENTION; COST-BENEFIT ANALYSIS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRIMARY PREVENTION; STOMACH NEOPLASMS; TAIWAN;

EID: 34250367923     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0286     Document Type: Note

References (2)

1. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC 1994;61:177.
2. Lee Y-C, Lin J-T, Wu H-M, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007;16:875-85.